August 8, 2017 08:22 AM EDT

Roche sells off its struggling IL-13 drug lebrikizumab in $1.4B Dermira deal

John Carroll

Editor & Founder

After watching its late-stage asthma program for its IL-13 drug lebrikizumab flounder with mixed and markedly unimpressive results, Roche is outlicensing the bulk of the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche sells off its struggling IL-13 drug lebrikizumab in $1.4B Dermira deal

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Roche sells off its strug­gling IL-13 drug le­brik­izum­ab in $1.4B Der­mi­ra deal

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Roche sells off its struggling IL-13 drug lebrikizumab in $1.4B Dermira deal